Company

About Hanmi

한미약품은 창조와 도전을 기치로 신약개발에 매진하는 R&D중심 제약기업입니다.

History

2019

  • Oct. Announced 2019 3Q earnings 265.7 billion won in sales, 20% R&D investment against sales
  • Spectrum, reapply Rolontis BLA to the FDA
  • The Korean doctor Association awarded Hanmi with a merit prize
  • Spectrum listed a clinical result of Poziotinib Posotinip study in the Kenssel medical journal
  • JVM, extension of pouch-roll production plant
  • Certified best institution for Human Resource Development (HRD) from government
  • Sep. Atenex, Releases clinical result of Oraxol in ESMO
  • Hanmi presents clinical trial results of Four clinical outcomes at EASD
  • Amosartan, 11th clinical outcomes listed in the SCI-class international journal
  • Signed a partnership with Phanes to develop dual and multiple antibodies
  • Amosartan Plus-Q, first entered in Latin America market
  • GMP inspectors from 10 Southeast Asian countries visited Paltan Smart Plant
  • Spectrum, disclosed Poziotinib
  • Hanmi selected as an Innovative pharmaceutical companies ranked No. 1 in Korea and No. 12 in Asia
  • Aug. Atenex Announce key clinical results of phase 3 clinial trial
  • Jul. Announced 2019 2Q earnings 270.4 billion won in sales, 17% R&D investment against sales
  • Spectrum added poziotinib cohort three study
  • Jun. CEO kwon Se Chang awared 'KASBP Appreciation Award’ at KASBP spring symposium
  • Confirms global competitiveness innovative drugs for NASH, rare diseases and targeted anti-cancer
  • Spectrum and Atenex Announce results of new drugs
  • Spectrum presents clinical trial results of Belvarafenib at AACR
  • May. Phase 3 results of “Rovelito” were published in the international journal
  • Spectrum "'poziotinib’ global phase 2 cohort two study patient collection completed"
  • Hanmi receives FDA orphan drug designation fin treatment of short bowel syndrome
  • Apr. JVM Packaging System, Launched in the Russian market
  • Genetech presents 4 results of clinical trial at AACR
  • Mar. Co promotion agreement of ‘Diquas’ with Santen
  • Received Seoul Metropolitan Government's Best Practices for Public Taxpayers
  • Rovelito Released clinical results of Phase 4 in the international journal
  • Feb. Hanmi Pharmaceutical-MPO, 7th concert was succesfully ended
  • Hanmi Pharmaceutical set up an audit committee
  • Jan. Announced 2018 earnings 1.16 trillion won in sales, 19% R&D investment against sales
  • Certified International Standard for Information Protection Management System (ISO27001)
  • Hanmi unveiled new R&D strategy at JP Morgan Healthcare Conference
  • Oraxol Global 3-phase patient collection completed
  • Spectrum "'poziotinib’ global phase 2 cohort one study patient collection completed"